Screening for Breast Cancer-Related Lymphedema in Targeted Therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, longitudinal study conducted at Massachusetts General Hospital to monitor the onset of breast cancer–related lymphedema (BCRL) in patients receiving targeted therapies for early or metastatic breast cancer. Researchers will measure arm volume changes using a Perometer and SOZO device from before treatment, throughout therapy, and for up to six months after treatment ends. The study aims to compare relative arm volume changes with reported symptoms to identify early indicators of edema. Approximately 166 participants will be enrolled under DF/HCC-regulated protocols at MGH.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.
* Subjects that will be eligible for the study include:
* Females between 18 and 80 years of age
* With a history of breast cancer
* 4 weeks or more post-surgery
* With or without edema
* Undergoing treatment with targeted therapy for early or metastatic disease.

Exclusion Criteria:

\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Alphonse G. Taghian, MD — Massachusetts General Hospital
• Study coordinator: Alphonse G. Taghian, MD
• Email: ataghian@partners.org
• Phone: 617-643-1306

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Program to prevent lymphedema after breast cancer surgery

  This study is testing a prevention program to help women who have breast cancer surgery avoid lymphedema by using treatments like lymphatic massage and special garments.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06144164

• Axillary Web Syndrome after Breast Cancer Surgery: Incidence, Risk Factors, and Outcomes

  This study tests how often AWS occurs after breast cancer surgery and what factors make it more likely, using a forward-looking approach in women undergoing SLNB or ALND.

  Recruiting at 2 sites Antalya City Hospital · Istanbul, BAGCILAR and 1 other locations · NCT07780240

• Nutrition awareness for women after non-metastatic breast cancer

  This online program tests whether an educational brochure and short surveys can help women who have finished treatment for non-metastatic breast cancer recognize unhealthy processed foods and be willing to change their diet.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07389967

• First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer

  This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT07299409

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.